Clinical trial
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung…
NCT00003313 · Radiation Therapy Oncology Group, Other · Completed
Key facts
| NCT number | NCT00003313 |
|---|---|
| Title | Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer |
| Official title | A Phase III Randomized Study of Amifostine Mucosal Protection for Patients With Favorable Performance Inoperable Stage II-III A/B Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Induction and Concurrent Hyperfractionated Radiotherapy With Paclitaxel and Carboplatin |
| Lead sponsor | Radiation Therapy Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH NRG Oncology |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity |
| Intervention type | Biological, Drug, Radiation |
| Interventions | filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy |
| Enrollment | 243 |
| Start date | Sep 1, 1998 |
| Primary completion | Jul 1, 2002 |
| Completion | Jun 1, 2010 |
| First posted | Nov 26, 2003 |
| Last update posted | Nov 21, 2014 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: